IDO1的mRNA递送抑制了T细胞介导的自身免疫
Laurie L Kenney1, Rebecca Suet-Yan Chiu1, Michelle N Dutra1
1Immune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Cell reports. Medicine
|September 7, 2024
概括
使者RNA (mRNA) 提供了一种新型的膜固的印度氨胺-2,3-二氧化酶 (IDO1),用于治疗自身免疫性疾病. 这种方法通过抑制免疫反应,在多种模型中成功地改善了疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 生物技术是生物技术.
背景情况:
- 氨酸-2,3-二氧化酶 (IDO) 调节免疫反应,通过降解托变成金氨酸途径代谢物.
- 在临床前模型中,IDO1 缺乏或阻塞会加剧自身免疫力和人类的敏感性.
- 目前针对自身免疫性疾病的IDO1的治疗策略有限.
研究的目的:
- 开发一种新的T细胞介导自身免疫的治疗策略,使用mRNA递送的,膜固的IDO1.1.
- 在多种自身免疫模型中调查膜固的IDO1在改善疾病严重性的有效性.
主要方法:
- 使用的信使RNA (mRNA) 在脂质纳米粒子 (LNPs) 中配制用于传递.
- 设计了一个人体IDO1变体,具有Src化化部位用于血 anchoring.
- 在实验性自身免疫脑膜炎 (EAE),大鼠原蛋白诱导性关节炎 (CIA) 和急性移植对宿主疾病 (aGVHD) 模型中测试了治疗疗效.
主要成果:
- 隔膜固的IDO1显示蛋白质的生产增加,并增强了代谢物转化.
- 治疗成功地改善了T细胞介导自身免疫的三个测试模型中的疾病.
- 治疗疗效与肝脏IDO1表达和全身托耗尽相关.
结论:
- 基于mRNA的膜定IDO1的输送是治疗T细胞介导的自身免疫性疾病的一个有前途的策略.
- 这种方法有效地通过调节 kynurenine 途径来抑制异常免疫反应.
- 该平台的进一步开发可能为自身免疫性疾病提供新的治疗途径.
相关概念视频
T Cell Types and Functions
963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K


